REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,264.00
Bid: 12,280.00
Ask: 12,282.00
Change: 146.00 (1.20%)
Spread: 2.00 (0.016%)
Open: 12,244.00
High: 12,384.00
Low: 12,228.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

Mon, 25th Mar 2024 07:59

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

The US Federal Reserve left rates unmoved, but a set of projections which accompanied its decision suggested three cuts are still in the offing this year.

The Bank of England also left its benchmark rate unmoved, but there is a growing conviction it will soon cut.

BoE Governor Andrew Bailey said that interest rates are in play this year, as signs that the risk of a wage-price spiral ebb. Bailey said he is increasingly confident that inflation is heading towards the bank's target in an interview with the Financial Times.

He signalled that markets were right to expect more than one interest rate cut this year, and stressed how small the technical recession last year had been.

In early UK corporate news, AstraZeneca announced a new drug approval in the US, while Kingfisher saw its annual profit fall.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called down 0.2% at 7,741.12

----------

Hang Seng: marginally lower at 16,492.09

Nikkei 225: closed down 1.2% at 40,414.12

S&P/ASX 200: closed up 0.5% at 7,811.90

----------

DJIA: closed down 305.47 points, 0.8%, at 39,475.90

S&P 500: closed down 7.35 points, 0.1%, at 5,234.18

Nasdaq Composite: closed down 26.98 points, 0.2%, to 16,428.82

----------

EUR: down at USD1.0821 (USD1.0829)

GBP: down at USD1.2607 (USD1.2627)

USD: down at JPY151.24 (JPY151.46)

Gold: down at USD2,167.90 per ounce (USD2,173.50)

(Brent): up at USD85.22 a barrel (USD85.15)

(changes since previous London equities close)

----------

ECONOMICS

----------

Monday's key economic events still to come:

14:15 GMT UK Bank of England MPC member Catherine Mann speaks

12:25 GMT US Atlanta Fed President Raphael Bostic speaks

12:30 GMT US Chicago Fed national activity index

14:00 GMT US new home sales

14:30 GMT US Dallas Fed manufacturing business index

14:30 GMT US Federal Reserve Governor Lisa Cook speaks

----------

Prime Minister Rishi Sunak will on Monday announce GBP200 million of public investment to boost the UK's nuclear deterrent programme and its civil nuclear industry, which the government says will support 40,000 expected new jobs. The government will partner with industry leaders including BAE Systems, Rolls-Royce and EDF and Babcock to invest at least GBP763 million by 2030 in skills, jobs and education, Sunak's Downing Street office said in a press release ahead of his announcement. The investment aims to ensure that the northern England town of Barrow-in-Furness, where Sunak will make the announcement, "thrives as the home of UK nuclear submarine-building".

----------

EVE Energy is set to build the biggest gigafactory in the UK, The Sunday Times reported. The Guangdong, China-based electric vehicle batteries producer counts BMW among its customers and is the world's largest manufacturer of "Tesla-like" cylindrical car batteries. The planned factory on the outskirts of Coventry will initially see a GBP1.2 billion investment from EVE Energy for an initial 20 gigawatt capacity, with that set to expand to 60 gigawatt in following phases. EVE Energy reportedly made a multi-billion pound commitment in a letter to UK Chancellor Jeremy Hunt. The plant would create around 6,000 jobs and thousands more in the supply chain.

----------

BROKER RATING CHANGES

----------

HSBC cuts Prudential price target to 1,150 (1,745) pence - 'buy'

----------

JPMorgan places Intertek on 'positive catalyst watch'

----------

COMPANIES - FTSE 100

----------

AstraZeneca said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat some adult suffers of central nervous system disorder neuromyelitis optica spectrum. The Cambridge-based pharmaceutical company said this was based on positive results from the Champion-NMOSD phase 3 trial, in which Ultomiris met its primary endpoint. NMOSD is a rare autoimmune disease that affects the central nervous system, including the spine and optic nerves. "The diagnosed prevalence of adults with NMOSD in the US is estimated at approximately 6,000," AstraZeneca said.

----------

Kingfisher reported a decline in annual sales and profit, though the B&Q and Screwfix owner hailed a "resilient" performance in its UK and Ireland operation. Pretax profit fell 22% to GBP475 million in the financial year that ended January 31 from GBP611 million a year earlier, while sales fell 0.6% to GBP12.98 billion from GBP13.06 billion. Kingfisher maintained its total dividend for the year at 12.40 pence per share. Chief Executive Officer Thierry Garnier said: "In the UK & Ireland, B&Q, TradePoint and Screwfix each delivered resilient sales and market share growth - in particular very strong gains at Screwfix. In France, where the market has been impacted by low consumer confidence, we have made significant adjustments to the cost base and started to embed e-commerce marketplace and trade customer initiatives similar to those successfully implemented in the UK. And in Poland, where we faced strong comparatives and a tough economic backdrop, sales trends are gradually improving in line with the consumer environment." Like-for-like sales so far in the first-quarter are down 2.3% on-year, it said. It expects adjusted pretax profit for the new year in the range of GBP490 million to GBP550 million, potentially a 14% decline from what was achieved in the year just gone. Adjusted pretax profit in financial 2024 fell 25% to GBP568 million from GBP758 million.

----------

COMPANIES - FTSE 250

----------

Octopus Renewables Infrastructure Trust said its net asset value per share at its December 31 year-end stood at 90.00 pence, down 10% from 100.00p a year earlier. The NAV total return for 2023 was 2.1%, slowing from 12.4% in 2022. Pretax profit fell 82% to GBP12.7 million from GBP69.8 million. Investment income rose 6.0% to GBP42.7 million from GBP40.3 million, but its bottom line was hurt by a negative GBP23.0 million movement in fair value of investments, swinging from a gain of GBP37.6 million the prior year. The total dividend for 2023, however, increased 10% to 5.79p from 5.24p. Looking ahead, it has increased its total dividend target for 2024 by 4.0% to 6.02p, which it said was in line with UK consumer price inflation. Chair Phil Austin commented: "Despite the market challenges experienced in the investment trust sector in recent months, the fundamental driving forces behind clean energy investment are stronger than ever, and we believe that ORIT is very well placed to continue its contribution to the transition to net zero whilst ensuring an attractive level of returns for our shareholders."

----------

OTHER COMPANIES

----------

Money transfer services provider Wise announced the appointment of Delivery Hero Chief Financial Officer Emmanuel Thomassin as its next CFO on Monday, replacing Matthew Briers who had signalled his intention to step down from the role last year. Wise said Briers will now leave with immediate effect, with Thomassin joining at the start of October and Senior Group Financial Director Kingsley Kemish serving as interim CFO in the meantime. Chair David Wells commented: "We're delighted to welcome Emmanuel as our new Chief Financial Officer after an extensive global search. A seasoned CFO, leader and board member with well over a decade's experience, Emmanuel has a proven track record of scaling companies in rapidly-evolving industries - from startups to public companies. I look forward to working with him as Wise continues on its path to reshape global financial services for the 21st century."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.